Answers are grounded in this paper and cite their sources.
Canagliflozin ameliorated adenine - induced CKD in rats, through reduction of several inflammatory and oxidative stress parameters, and other indices such as uremic toxins, and by antagonizing the increase in the renal content of the transcription factor Nrf2. The drug caused no overt or significant untoward effects, and its trial in patients with CKD may be warranted.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: